JP2023502780A - 腫瘍浸潤リンパ球の活性化及び増殖方法 - Google Patents

腫瘍浸潤リンパ球の活性化及び増殖方法 Download PDF

Info

Publication number
JP2023502780A
JP2023502780A JP2022530237A JP2022530237A JP2023502780A JP 2023502780 A JP2023502780 A JP 2023502780A JP 2022530237 A JP2022530237 A JP 2022530237A JP 2022530237 A JP2022530237 A JP 2022530237A JP 2023502780 A JP2023502780 A JP 2023502780A
Authority
JP
Japan
Prior art keywords
tils
population
agonist
days
expanded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022530237A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021108455A5 (https=
JP2023502780A5 (https=
Inventor
マイカ ベンソン，
ニコラス ジョン コレッティ，
ノア ジェイコブ トゥボ，
マイケル シュラバック，
Original Assignee
ケーエスキュー セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケーエスキュー セラピューティクス， インコーポレイテッド filed Critical ケーエスキュー セラピューティクス， インコーポレイテッド
Publication of JP2023502780A publication Critical patent/JP2023502780A/ja
Publication of JPWO2021108455A5 publication Critical patent/JPWO2021108455A5/ja
Publication of JP2023502780A5 publication Critical patent/JP2023502780A5/ja
Priority to JP2025133444A priority Critical patent/JP2025159098A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022530237A 2019-11-25 2020-11-24 腫瘍浸潤リンパ球の活性化及び増殖方法 Withdrawn JP2023502780A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025133444A JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940035P 2019-11-25 2019-11-25
US62/940,035 2019-11-25
US202063081539P 2020-09-22 2020-09-22
US63/081,539 2020-09-22
PCT/US2020/062094 WO2021108455A1 (en) 2019-11-25 2020-11-24 Methods for activation and expansion of tumor infiltrating lymphocytes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025133444A Division JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Publications (3)

Publication Number Publication Date
JP2023502780A true JP2023502780A (ja) 2023-01-25
JPWO2021108455A5 JPWO2021108455A5 (https=) 2023-12-01
JP2023502780A5 JP2023502780A5 (https=) 2023-12-01

Family

ID=76128945

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022530237A Withdrawn JP2023502780A (ja) 2019-11-25 2020-11-24 腫瘍浸潤リンパ球の活性化及び増殖方法
JP2025133444A Pending JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025133444A Pending JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Country Status (8)

Country Link
US (1) US20240376428A1 (https=)
EP (1) EP4065233A4 (https=)
JP (2) JP2023502780A (https=)
KR (1) KR20220119038A (https=)
CN (1) CN115003387A (https=)
AU (1) AU2020392094A1 (https=)
CA (1) CA3162272A1 (https=)
WO (1) WO2021108455A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
WO2021252804A1 (en) 2020-06-12 2021-12-16 Nkarta, Inc. Genetically modified natural killer cells for cd70-directed cancer immunotherapy
CN114901805B (zh) 2020-11-19 2023-07-25 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的培养方法及其用途
CN117616115A (zh) * 2021-08-03 2024-02-27 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
WO2023039410A1 (en) * 2021-09-08 2023-03-16 KSQ Therapeutics, Inc. Lymphocyte potency assay
CN118414422A (zh) * 2021-12-30 2024-07-30 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
WO2023138598A1 (zh) * 2022-01-19 2023-07-27 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞在疾病治疗中的用途
EP4471128A4 (en) * 2022-01-29 2026-03-04 Suzhou Grit Biotechnology Co Ltd Modified tumor infiltrating lymphocyte and use thereof
CA3254363A1 (en) * 2022-03-07 2023-09-14 Nkarta, Inc. Multiplex gene-edited cells for CD70-led cancer immunotherapy
CN117417894A (zh) * 2023-09-15 2024-01-19 毕诺济(上海)生物技术有限公司 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用
WO2025092690A1 (zh) * 2023-10-30 2025-05-08 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008522951A (ja) * 2004-07-19 2008-07-03 ベイラー・カレツジ・オブ・メデイシン サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
WO2010098429A1 (ja) * 2009-02-27 2010-09-02 国立大学法人大阪大学 免疫アジュバント組成物、及びその利用
JP2015533493A (ja) * 2012-09-25 2015-11-26 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 可動性ナノマトリックスによるｔ細胞のポリクローナル刺激方法
JP2017524348A (ja) * 2014-06-10 2017-08-31 モナッシュ ユニバーシティ 養子細胞移入のためのｐｔｐｎ２阻害を用いた白血球の産生方法
JP2017528133A (ja) * 2014-09-04 2017-09-28 ステムセル テクノロジーズ インコーポレーティッド Ｔ細胞またはｎｋ細胞を活性化および増加させるための、可溶性抗体複合体
CN108753718A (zh) * 2018-06-20 2018-11-06 淮安诺康生物科技有限公司 肿瘤浸润淋巴细胞til的体外扩增方法
WO2018209115A1 (en) * 2017-05-10 2018-11-15 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2019178421A1 (en) * 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2019178420A1 (en) * 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
JP2019531744A (ja) * 2016-10-31 2019-11-07 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球拡大培養用の改変人工抗原提示細胞

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3197849A1 (en) * 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
SG11201708516YA (en) * 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2017087784A1 (en) * 2015-11-18 2017-05-26 Duke University Tumor infiltrating lymphocytes for treatment of cancer

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008522951A (ja) * 2004-07-19 2008-07-03 ベイラー・カレツジ・オブ・メデイシン サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
WO2010098429A1 (ja) * 2009-02-27 2010-09-02 国立大学法人大阪大学 免疫アジュバント組成物、及びその利用
JP2015533493A (ja) * 2012-09-25 2015-11-26 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 可動性ナノマトリックスによるｔ細胞のポリクローナル刺激方法
JP2017524348A (ja) * 2014-06-10 2017-08-31 モナッシュ ユニバーシティ 養子細胞移入のためのｐｔｐｎ２阻害を用いた白血球の産生方法
JP2017528133A (ja) * 2014-09-04 2017-09-28 ステムセル テクノロジーズ インコーポレーティッド Ｔ細胞またはｎｋ細胞を活性化および増加させるための、可溶性抗体複合体
JP2019531744A (ja) * 2016-10-31 2019-11-07 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球拡大培養用の改変人工抗原提示細胞
WO2018209115A1 (en) * 2017-05-10 2018-11-15 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2019178421A1 (en) * 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2019178420A1 (en) * 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
CN108753718A (zh) * 2018-06-20 2018-11-06 淮安诺康生物科技有限公司 肿瘤浸润淋巴细胞til的体外扩增方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIANCA HEEMSKERK ET AL., CANCER IMMUNOLOGY RESEARCH, vol. 7 (2_Supplement): B016, JPN6024044020, 1 February 2019 (2019-02-01), ISSN: 0005569907 *
MARCEL J. FLENS ET AL., CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 37, JPN6024044019, 1993, pages 323 - 328, ISSN: 0005569906 *
MARIE-ANDREE FORGET ET AL., FRONTIERS IN IMMUNOLOGY, vol. Vol. 8, Article 908, JPN6024044017, 2017, pages 1 - 8, ISSN: 0005569905 *
QUNRUI YE ET AL., JOURNAL OF TRANSLATIONAL MEDICINE, vol. 9:131, JPN6024044015, 2011, pages 1 - 13, ISSN: 0005569904 *

Also Published As

Publication number Publication date
CA3162272A1 (en) 2021-06-03
AU2020392094A1 (en) 2022-06-23
WO2021108455A1 (en) 2021-06-03
US20240376428A1 (en) 2024-11-14
EP4065233A1 (en) 2022-10-05
EP4065233A4 (en) 2024-07-10
JP2025159098A (ja) 2025-10-17
KR20220119038A (ko) 2022-08-26
CN115003387A (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
JP7847385B2 (ja) 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
JP2025159098A (ja) 腫瘍浸潤リンパ球の活性化及び増殖方法
US20230108584A1 (en) Methods for activation and expansion of tumor infiltrating lymphocytes
JP7781761B2 (ja) キメラ抗原受容体発現細胞を作製する方法
US10738278B2 (en) Engineered cells for adoptive cell therapy
JP2024111155A (ja) 免疫療法の改善のための遺伝子標的の組み合わせ
JP2024081796A (ja) 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
JP2023516008A (ja) キメラ抗原受容体発現細胞を作製する方法
JP2021518162A (ja) 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
TW202538050A (zh) 製備表現嵌合抗原受體的細胞之方法
TW202241508A (zh) 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
JP2021518161A6 (ja) 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
CN112040987A (zh) 用于改进的免疫疗法的基因调控组合物和方法
KR20200142037A (ko) 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제
CN116529266A (zh) 用于将核酸递送到细胞的组合物和方法
TW202346573A (zh) 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
CN117940557A (zh) 制备经修饰的肿瘤浸润性淋巴细胞的方法及其在过继性细胞治疗中的应用
JP2022512915A (ja) 改良された腫瘍反応性ｔ細胞の選択

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250826